MedTrace Logo

A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults

NCT06661694 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-04-24

No results posted yet for this study

Summary

The purpose of the study is to compare the amount of mevrometostat available from four different tablet formulations, taken with food, in healthy adult participants.

This study is seeking male or female participants who:

* are 18 years or older
* are healthy as decided by medical tests.
* have a Body mass index (BMI) of 16 to 32 kilogram per meter squared
* a total body weight of more than 50 kilograms (110 pounds).

All participants will take part in 4 study periods to receive 4 different treatments, which are assigned in a random order. There will also be a 5-day gap between each study period. This is done so that the medicine is passed out of the body before the start of the next period.

Each treatment consists of a single dose of mevrometostat (PF-06821497), and the treatments differ only by tablet formulation.

How the medicine is processed in the body will be studied after giving the medicines to the participants. This will be done by collecting blood samples after giving each of these tablets. The results will be used to see the effect of tablet formulation on the amount of mevrometostat (PF-06821497) available in the blood of the participants.

Participants will be in the study for about 12 weeks.

Conditions

  • Healthy

Interventions

DRUG

Treatment A

Single 875 mg dose of mevrometostat standard tablet formulation

DRUG

Treatment B

Single 875 mg dose of mevrometostat alternative tablet formulation

DRUG

Treatment C

Single 875 mg dose of mevrometostat alternative tablet formulation

DRUG

Treatment D

Single 875 mg dose of mevrometostat alternative tablet formulation

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2025-09-08
Completion
2025-09-09

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06661694 on ClinicalTrials.gov